Royalty Pharma (RPRX) EBITDA Margin (2019 - 2026)

Royalty Pharma has disclosed EBITDA Margin across 8 years of filings, most recently posting 19.75% for Q2 2026.

• In Q2 2026, EBITDA Margin fell 1651.0% year-over-year to 19.75%; the TTM figure through Jun 2026 stood at 59.61% (down 2023.0% YoY), while the FY2025 annual figure was 65.58%, up 848.0% from the prior year.
• EBITDA Margin came in at 19.75% for Q2 2026 at Royalty Pharma, down from 89.29% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 130.17% in Q3 2024 to a low of 85.31% in Q4 2022.
• Average EBITDA Margin over 5 years is 50.29%, with a median of 55.54% recorded in 2024.
• Year-over-year, EBITDA Margin plunged 11196 bps in 2022 and jumped 18814 bps in 2023.
• Over 5 years, EBITDA Margin stood at 85.31% in 2022, then surged by 221 bps to 102.82% in 2023, then sank by 41 bps to 60.9% in 2024, then increased by 3 bps to 62.44% in 2025, then plunged by 68 bps to 19.75% in 2026.
• Per Business Quant data, the three most recent EBITDA Margin figures were 19.75% in Q2 2026, 89.29% in Q1 2026, and 62.44% in Q4 2025.